Zhitong Finance App News, Shiyao Innovation (300765.SZ) announced that the company's holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as “Jushi Bio”), has recently launched an open, multi-queue, multi-center phase II clinical trial to evaluate the efficacy and safety of SYS6041 in combination therapy for recurrent ovarian cancer.

Zhitong Finance App News, Shiyao Innovation (300765.SZ) announced that the company's holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as “Jushi Bio”), has recently launched an open, multi-queue, multi-center phase II clinical trial to evaluate the efficacy and safety of SYS6041 in combination therapy for recurrent ovarian cancer.